Continuos clinical remission with biologics in Ulcerative Colitis: the A.U.R.O.R.A. comparative study

Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conflicting results. After patent expire of infliximab originator, adalimumab, infliximab biosimilar, golimumab and vedolizumab have been approved in Italy.We compared the efficacy of these four biologics in UC according to the concept of continuous clinical remission (CCR)

Corrosion behaviour of porous Ti intended for biomedical applications

Porous Ti implants are being developed inorder to reduce the biomechanical mismatch between theimplant and the bone, as well as increasing the osseointegrationby improving the bone in-growth. Most of the focusin the literature has been on the structural, biological andmechanical characterization of porous Ti whereas there islimited information on the electrochemical characterization.Therefore, the present work aims to study the corrosionbehaviour of porous Ti having 30 and 50 % ofnominal porosity, produced by powder metallurgy routeusing the space holder technique. The percentage, size anddistribution of the pores were determined by image analysis.Electrochemical tests consisting of potentiodynamicpolarization and electrochemical impedance spectroscopywere performed in 9 g/L NaCl solution at body temperature.Electrochemical studies revealed that samples presenteda less stable oxide film at increased porosity, morespecifically, the complex geometry and the interconnectivityof the pores resulted in formation of less protectiveoxide film in the pores.This study was supported by FCT with the reference project UID/EEA/04436/2013, by FEDER funds through the COMPETE 2020 – Programa Operacional Competitividade e Internacionalizac¸a˜o (POCI) with the reference project POCI-01-0145- FEDER-006941, Programa de Acc¸o˜es Universita´rias Integradas LusoFrancesas’ (PAUILF TC-12_14), and The Calouste Gulbenkian Foundation through ‘‘Programa de Mobilidade Acade´mica para Professores’’. The authors would also like to acknowledge Prof. Ana Senos (University of Aveiro) and Prof. Jose´ Carlos Teixeira (University of Minho) for the provision of the characterization facilities.info:eu-repo/semantics/publishedVersio

Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. Weevaluated whether PSVs inBRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 30 region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71-4.68; P = 0.00004) and elevated risk of Gleason 8+prostate cancer (HR = 4.95; 95% CI, 2.12-11.54; P = 0.0002). No genotype-phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer. Significance: Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific BRCA2 mutation inherited by the at-risk individual.Peer reviewe